A novel nano‐immunotherapeutic remodels the immune landscape of malignant pleural effusion: Insights into its mechanism of action through single‐cell RNA‐sequencing

Clinical evidence indicates that the microenvironment in malignant pleural effusion (MPE) is immunologically cold, which impairs tumour immunosurveillance and antitumor immune response to immune checkpoint blockade (ICB). In a recent issue of Nature Nanotechnology, Liu et al. demonstrate a new nanot...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational medicine 2022-03, Vol.12 (3), p.e774-n/a
Main Authors: Liu, Yang, Zhao, Dawen
Format: Article
Language:English
Subjects:
Antigens
anti‐PD‐L1 immunotherapy
Cancer
Clinical medicine
Cold
Cytokines
Humans
Immune Checkpoint Inhibitors
Immunology
Immunotherapy
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Lymphocytes
malignant pleural effusion
Medical prognosis
Mesothelioma
nanoparticle immunotherapeutic
Nanoparticles
Neutrophils
Pleural effusion
Pleural Effusion, Malignant - drug therapy
Pleural Effusion, Malignant - genetics
RNA - pharmacology
RNA - therapeutic use
single‐cell RNA sequencing
Tumor Microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical evidence indicates that the microenvironment in malignant pleural effusion (MPE) is immunologically cold, which impairs tumour immunosurveillance and antitumor immune response to immune checkpoint blockade (ICB). In a recent issue of Nature Nanotechnology, Liu et al. demonstrate a new nanotechnological approach to effectively mitigate the immune cold MPE and provide insights into its mechanism of action through single‐cell RNA‐sequencing.
ISSN:2001-1326
2001-1326
DOI:10.1002/ctm2.774